Roche Holding AG announced today that it has asked EU health authorities to re-examine data related to approving the pancreatic cancer treatment Tarceva. The European Committee for Medicinal Products for Human Use (CHMP) had recently rejected the Tarceva application.
''People with pancreatic cancer need new treatment options like Tarceva, which has been proven in clinical trials to significantly increase survival and has already been approved for this indication in the US,'' Roche said in a statement.
AdvertisementThe Swiss company added that Tarceva was the first drug to show survival benefit in patients with the cancer.
You May Also Like